BLIS Technologies Limited develops and sells probiotics in New Zealand, the Asia Pacific, Europe, the Middle East, Africa, and North America. It offers BLIS K12, an oral probiotic that supports ear, nose, and throat health, as well as immunity and bad breath; BLIS M18, an oral probiotic for teeth and gums health; and BLIS Q24, a probiotic that balances the skin microbiome and restores skin's health. The company's products are used in various health areas, including ear, nose, throat, immune, dental, and skin, as well as pet oral. It exports its products. The company was formerly known as Tarn Holdings Limited and changed its name to BLIS Technologies Limited in August 2000. BLIS Technologies Limited was incorporated in 2000 and is headquartered in Dunedin, New Zealand.
Frequently asked questions
What sector does BLIS Technologies Limited (BLT) operate in?
BLIS Technologies Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BLIS Technologies Limited (BLT) current stock price?
As of the latest data, BLIS Technologies Limited stock price is NZ$0.02, with a previous close of NZ$0.02.
What is BLIS Technologies Limited (BLT) current market capitalization?
BLIS Technologies Limited market cap is approximately 23.03 million.
Does BLIS Technologies Limited (BLT) pay dividends?
No. BLIS Technologies Limited does not pay a dividend.
What is BLIS Technologies Limited (BLT) beta (volatility) score?
BLIS Technologies Limited has a beta of 0.636, indicating lower volatility than the overall market.
